Germ cell tumors

Current Opinion in Oncology

Volumn 17, Issue 3, 2005, Pages 268-274

  Hussain, Arif ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Chemotherapy; Expression profiling; Germ cell tumors; Nonseminomatous germ cell tumor; Radiation; Seminoma; Tumor resection

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; VINCRISTINE SULFATE;

CLINICAL TRIAL; DIARRHEA; ETHNOLOGY; GEOGRAPHY; GERM CELL TUMOR; HUMAN; INCIDENCE; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEMINOMA; SIDE EFFECT;

GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK FACTORS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 17844401995     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000160750.33552.42     Document Type: Review

References (46)

1. Richiardi L, Bellocco R, Adami HO, et al. Testicular cancer incidence in eight Northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev 2004; 13:2157-2166. The study demonstrates that significant differences in the geographic distribution of GCT exist within different regions of Europe, and confirms the overall increasing incidence of this malignancy.
2. McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003; 97:63-70.
3. Biggs ML, Schwartz SM. Differences in testis cancer survival by race and ethnicity: a population based study, 1973-1999 (United States). Cancer Causes Control 2004; 15:437-444. This large analysis of 16,086 cases of primary testicular cancer diagnosed between 1973 and 1999 further confirms the ethnic disparities that exist with respect to stage at diagnosis and risk of dying from testicular cancer, even after adjusting for various parameters such as tumor stage and histology.
4. Hardell L, Van Bavel B, Lindstrom G, et al. Concentrations of polychlorinated biphenyls in blood and the risk for testicular cancer. Int J Androl 2004; 27:282-290.
5. Srivastava A, Kreiger N. Cigarette smoking and testicular cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:49-54.
6. Garner MJ, Birkett NJ, Johnson KC, et al. Dietary risk factors for testicular carcinoma. Int J Cancer 2003; 106:934-941.
7. Hardell L, Malmqvist N, Ohlson GC, et al. Testicular cancer and occupational exposure to polyvinyl chloride plastics: a case-control study. Int J Cancer 2004; 109:425-429.
8. Gundy S, Babosa M, Baki M, Bodrogi I. Increased predisposition to cancer in brothers and offspring of testicular cancer. Pathol Oncol Res 2004; 10:197-203.
9. Vistisen K, Loft S, Olsen JH, et al. Low CYP1A2 activity associated with testicular cancer. Carcinogenesis 2004; 25:923-929.
10. Ringdahl E, Claybrook K, Teague JL, Northrup M. Testicular microlithiasis and its relation to testicular cancer on ultrasound findings of symptomatic men. J Urol 2004; 172:1904-1906.
11. de Gouveia Brazao CA, Pierik FH, Oosterhuis JW, et al. Bilateral testicular microlithiasis predicts the presence of the precursor of testicular germ cell tumors in subfertile men. J Urol 2004; 171:158-160.
12. Almstrup K, Hoei-Hansen CE, Wirkner U, et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res 2004; 64:4736-4743. A significant overlap in gene expression patterns between testicular CIS and embryonic stem cells is demonstrated, consistent with the known pluripotent nature of TCIS, which is the common precursor for the diverse histological subtypes of GCTs.
13. Bowles J, Teasdale RP, James K, Koopman P. Dppa3 is a marker of pluripotency and has human homologue that is expressed in germ cell tumors. Cytogenet Genome Res 2003; 101:261-265.
14. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004; 164:305-313.
15. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005; 23:49-57. An extensive analysis of the relative incidence of KIT mutations and KIT expression in a range of non-hematologic malignancies.
16. Rapley EA, Hockley S, Warren W, et al. Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer 2004; 90:2397-2401.
17. Looijenga LH, de Leeuw H, van Oorschot M, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003; 63:7674-7678.
18. Skotheim RI, Korkmaz KS, Klokk TI, et al. NKX3.1 expression is lost in testicular germ cell tumors. Am J Pathol 2003; 163:2149-2154.
19. Kamai T, Yamanishi T, Shirataki H, et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 2004; 10:4799-4805.
20. Hatakeyama S, Ohyama C, Minagawa S, et al. Functional correlation of trophinin expression with the malignancy of testicular germ cell tumor. Cancer Res 2004; 64:4257-4262. With increasing tumor stage, a greater proportion of patients with GCT were found to express trophinin, a molecule involved in cell adhesion, on immunohistochemistry. Further, introduction of a cDNA encoding trophinin into JKT-1 cells increased the metastatic behavior of the orthotopically implanted transfectants in nude mice, demonstrating that trophinin may enhance GCT invasiveness.
21. Port M, Schmelz HU, Stockinger M, et al. Gene expression profiling in seminoma and nonseminoma. J Clin Oncol 2005; 23:58-69. An interesting study demonstrating that within the gene set examined there is overall under-expression of genes in NSGCTs compared with seminomas.
22. Sugimura J, Foster RS, Cummings OW, et al. Gene expression profiling of early-and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res 2004; 10:2368-2378. This study demonstrates that specific gene expression profiles correlate with the different histological subtypes of NSGCT. Moreover, specific gene expression patterns may distinguish outcome to treatment (early versus late relapse) within a specific subtype of NSGCT, such as yolk sac tumors.
23. Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004; 22:3868-3876. Based on serum tumor markers at baseline and after one cycle of chemotherapy in 653 patients with NSGCT, the time to normalization (TTN) of the markers was calculated via a log transformation function. Outcome in terms of 4-year PFS and OS in poor prognosis patients correlated with the predicted TTN of the tumor markers.
24. De Wit R, Collette L, Sylvester R, et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 1998; 78:1350-1355.
25. Mazumdar M, Bajorin DF, Bacik J, et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19:2534-2541.
26. Stevens MJ, Norman AR, Dearnaley DP, et al. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 1995; 13:87-92.
27. De Wit R, Sylvester R, Tsitsa C, et al. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. Br J Cancer 1997; 75:432-435.
28. Toner GC. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use. J Clin Oncol 2004; 22:3842-3845. A thoughtful discussion on the various issues surrounding the use of serum tumor marker decline in assessing treatment outcomes.
29. Kawakami T, Okamoto K, Ogawa O, Okada Y. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 2004; 363:40-42. An elegant application of a methylation-sensitive PCR assay to analyze methylation status of the XIST 5′ end gene in tumor tissue (97% of XIST alleles unmethylated) and plasma (64% alleles unmethylated) of GCT patients. Although unmethylated 5′ end XIST alleles were detected only in the plasma of GCT patients, sensitivity of the assay must be enhanced.
30. 18fluoro-deoxy- D-glucose positron emission tomography is a reliable predictor for viable tumor in post-chemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22:1034-1039. The role of FDG PET in assessing residual lesion after chemotherapy in patients with seminoma was determined. In 19 of 19 patients with lesions > 3 cm and 35 of 37 patients with lesions between 1 and 3 cm, FDG PET correctly predicted for viable tumor.
31. Ganjoo KN, Chan RJ, Sharma M, Einhorn L. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999; 17:3457-3460.
32. Oliver RT, Ong J, Shamash J, et al. Long term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage I nonseminoma treated with adjuvant chemotherapy. Urology 2004; 63:556-561.
33. Chevreau C, Mazerolles C, Soulie M, et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 2004; 46:209-214.
34. Kondagunta GV, Sheinfield J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004; 22:464-467. This study, with long-term follow-up data, further substantiates the efficacy of two cycles of etoposide/cisplatin chemotherapy in completely resected pathologic stage II NSGCT.
35. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German testicular cancer study group. J Clin Oncol 2004; 22:108-114. In this pilot phase II study, 46% overall response is demonstrated with combination gemcitabine/oxaliplatin chemotherapy in heavily pre-treated relapsed or refractory GCT patients, with acceptable toxicity (9% incidence of neutropenic fever).
36. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol 2004; 46:216-221.
37. Albers P, Weissbach L, Krege S, et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 2004; 171:1835-1838.
38. Schneider BP, Kesler KA, Brooks JA, et al. Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer. J Clin Oncol 2004; 22:1195-1200. In patients with primary mediastinal NSGCT, this retrospective review of outcomes underscores the importance of resecting all residual tumors post chemotherapy.
39. Rick O, Bokemeyer C, Weinknecht S, et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2004; 22:3713-3719. Similar to the above report, this study demonstrates that in patients with relapsed or refractory GCT treated with salvage and high-dose chemotherapy, resection of residual tumor can provide long-term disease control in a subset of patients, thus emphasizing the need to attempt surgical resection in all such patients if feasible.
40. Logue JP, Harris MA, Livsey JE, et al. Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 2003; 57: 1304-1309.
41. Classen J, Schmidberger H, Meisner C, et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German Testicular Cancer Study Group (GTCSG). Br J Cancer 2004; 90:2305-2311.
42. Zagars GK, Ballo MT, Lee AK, Strom S. Mortality after cure of testicular seminoma. J Clin Oncol 2004; 22:640-647. In patients with excellent prognosis, such as stage I seminoma treated with paraaortic radiation post orchiectomy, greater mortality than expected occurs during long-term follow-up (particularly greater than 15 years), including cardiac and non-seminoma cancer deaths. This is true even in patients who received no prophylactic mediastinal radiation.
43. Houck W, Abonour R, Vance G, et al. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol 2004; 22:2155-2158.
44. Thomas C, Cans C, Pelletier R, et al. No long-term increase in sperm aneuploidy rates after anticancer therapy: sperm fluorescence in situ hybridization analysis in 26 patients treated for testicular cancer or lymphoma. Clin Cancer Res 2004; 10:6535-6543.
45. Stahl O, Eberhard J, Jepson K, et al. The impact of testicular carcinoma and its treatment on sperm DNA integrity. Cancer 2004; 100:1137-1144.
46. Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004; 100:732-737.